June 13, 2019 / 5:37 AM / 4 days ago

BRIEF-AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005

June 13 (Reuters) - AB SCIENCE SA:

* ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER

* STUDY AB12005 IS INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 CONFIRMATORY STUDY OF MASITINIB IN FIRST-LINE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER PATIENTS WITH PAIN AT BASELINE OR TAKING OPIOIDS

* PROBABILITY OF SUCCESS OF STUDY AB12005 IS ABOVE 80% IN THE SELECTED SUB-POPULATION

* CO EXPECTS TO REPORT THE FINAL RESULTS FROM STUDY AB12005 IN 2020

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below